Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
Conditions
- Ovarian Epithelial Cancer Recurrent
Interventions
- DRUG: Trabectedin and Pegylated Liposomal Doxorubicin
Sponsor
Grupo Español de Investigación en Cáncer de Ovario
Collaborators